April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Macular Laser Photocoagulation Combined with Intravitreal Bevacizumab or Triamcinolone for Diabetic Macular Edema
Author Affiliations & Notes
  • Felipe P. Almeida
    Ophthalmology,
    University of Sao Paulo, Ribeirao Preto, Brazil
  • Bianka Y. Katayama
    Ophthalmology,
    University of Sao Paulo, Ribeirao Preto, Brazil
  • Andre Messias
    Ophthalmology,
    University of Sao Paulo, Ribeirao Preto, Brazil
  • Morgana Fisher
    Ophthalmology,
    University of Sao Paulo, Ribeirao Preto, Brazil
  • Maria Letícia Paccola
    Ophthalmology,
    University of Sao Paulo, Ribeirao Preto, Brazil
  • Rogerio A. Costa
    Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, Brazil
  • Ingrid U. Scott
    Ophthalmology & Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania
  • Rodrigo Jorge
    Ophthalmology, Ribeirao Preto Med Sch,
    University of Sao Paulo, Ribeirao Preto, Brazil
  • Footnotes
    Commercial Relationships  Felipe P. Almeida, None; Bianka Y. Katayama, None; Andre Messias, None; Morgana Fisher, None; Maria Letícia Paccola, None; Rogerio A. Costa, None; Ingrid U. Scott, None; Rodrigo Jorge, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1300. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Felipe P. Almeida, Bianka Y. Katayama, Andre Messias, Morgana Fisher, Maria Letícia Paccola, Rogerio A. Costa, Ingrid U. Scott, Rodrigo Jorge; Macular Laser Photocoagulation Combined with Intravitreal Bevacizumab or Triamcinolone for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1300.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the effects of macular laser photocoagulation combined with intravitreal injection of 1.5 mg bevacizumab (IVB) or 4 mg triamcinolone acetonide (IVT) for diabetic macular edema (DME).

Methods: : 49 patients (64 eyes) with DME were randomly assigned to one of three study groups: focal/grid macular laser (Laser; n=23), laser plus IVB (IVB; n=21), or laser plus IVT (IVT; n=20). Laser was performed 4 weeks after injection. Retreatment was performed at weeks 20 and 40 if central subfield macular thickness (CSMT) higher than 275 µm. Outcome measures included best-corrected visual acuity (BCVA), CSMT measured by optical coherence tomography, and intraocular pressure (IOP) measured at baseline and at 4, 8, 12, 16, 24, 36, and 52 weeks after treatment.

Results: : 31 patients completed the 52-week study period (Laser: n=17 eyes; IVB: n=13; IVT n=12;). At baseline, mean ± SE BCVA (logMAR) was 0.65 ± 0.08; 0.63 ± 0.07; 0.68 ± 0.06 in the Laser, IVB, and IVT groups respectively (P=0.8888). Statistically significant improvement in BCVA from baseline was observed within IVT group at weeks 16, 24 and 36. Mean ± SE BCVA (LogMAR) intra-individual difference to baseline was respectively: 0.19 ± 0.07 (P=0.0212), 0.23 ± 0.10 (P=0.0300), 0.25 ± 0.09 (P=0.0147). However, intergroup analyses revealed no differences between BCVA changes in any of the groups throughout the study period. At baseline, mean ± SE CSMT (µm) was 421.4 ± 122.6; 410.2 ± 88.0; 402.3 ± 85.2 in the laser, IVB, and IVT groups, respectively (P=0.8722). Significant reduction in CSMT was observed at all study periods in all 3 groups (P<0.05). No significant difference between groups’ CSMT change was observed in any study period (P>0.05). In the IVT group, IOP was significantly higher at 8 weeks after injection (P<0.05).

Conclusions: : One-year results showed no difference between CSMT improvements found after Laser with or without IVT or IVB association. The association of LASER and IVT was the only one associated with significant improvement in BCVA.

Clinical Trial: : http://www.clinicaltrials.gov NCT 00997191

Keywords: diabetic retinopathy • laser • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×